Also known as: Huntington's disease, Huntington's chorea, HD
Adult-onset form typically manifests ages 30-50; juvenile-onset (10% of cases) presents before age 20, often with more rigid phenotype and rapid progression. Affects males and females equally. Autosomal dominant inheritance means 50% of children of affected parent will inherit the disease.
Clinical trials are evaluating huntingtin-lowering strategies including antisense oligonucleotides (like gantenerumab) that reduce mutant huntingtin levels, gene-silencing approaches, and neuroprotective therapies. The Huntington's Disease Society of America and patient registries provide comprehensive trial information. Genetic testing and predictive testing for at-risk family members is available and recommended. If you have a family history of HD, consider genetic counseling and testing. Several promising drugs are in Phase 3 trials showing ability to slow cognitive and motor decline. Early treatment initiation with emerging therapies may be important, so discuss trial participation with your neurologist.
Duchenne muscular dystrophy is an X-linked genetic disorder causing progressive muscle weakness and degeneration, beginn...
Spinal muscular atrophy is an autosomal recessive genetic disorder affecting motor neurons in the spinal cord, causing p...
Myasthenia gravis is a chronic autoimmune neuromuscular disorder causing muscle weakness and rapid fatigue. Antibodies a...